Wall Street equity research analysts tracking Tenaya Therapeutics issue 12-month consensus price targets that sit significantly above its current micro-cap trading levels, reflecting speculative upside optimism tied to upcoming clinical trial milestones. However, analysts emphasize that these forecasts carry high volatility and depend on positive pipeline data and effective management of operational cash runways.